Valneva USA
Valneva USA, Inc.
4550 Montgomery Ave., Suite 460
Bethesda, MD 20814
Phone: (833) 403-8778Website: https://www.valneva.us/en/
Latest news
- FDA Approves Ixchiq (Chikungunya Vaccine, Live) for the Prevention of Disease Caused by Chikungunya Virus
10 November 2023 - Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate
14 August 2023 - Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
13 June 2023 - Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate
23 December 2022 - Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
25 May 2022 - Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
5 August 2021 - Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
7 July 2021 - Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate
21 December 2018
Drugs Associated with Valneva USA, Inc.
Valneva USA, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Ixchiq
Generic name: chikungunya vaccine, live (cvx 317) Drug class: viral vaccines |
||
|
Ixiaro
Generic name: japanese enceph vacc sa14-14-2, inactivated Drug class: viral vaccines |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||